Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Program to Provide Donations to Non-Profit Organizations Aligned with Corporate Values Deadline for Applications is August 3, 2026 SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program.

04.06.2026

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

01.06.2026

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

27.05.2026

Cytokinetics to Participate in June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in June:

27.05.2026

Cytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks Transcript

22.05.2026

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise

Cytokinetics NASDAQ: CYTK executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug's label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capital Markets.

Видео

28.10.2025

Positive

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
CYTK	Raymond James	Market Perform	undefined >> undefined	July 30th 2025

Пресс-релизы

08.06.2026

Cytokinetics, Incorporated (CYTK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты